Reversing a model of Parkinson's disease with in situ converted nigral neurons.

Animals Astrocytes / cytology Axons / physiology Disease Models, Animal Dopamine / biosynthesis Dopaminergic Neurons / cytology Female Heterogeneous-Nuclear Ribonucleoproteins / deficiency Humans In Vitro Techniques Male Mice Neostriatum / cytology Neural Pathways Neurogenesis Parkinson Disease / metabolism Phenotype Polypyrimidine Tract-Binding Protein / deficiency Substantia Nigra / cytology

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
06 2020
Historique:
received: 12 11 2018
accepted: 13 05 2020
entrez: 26 6 2020
pubmed: 26 6 2020
medline: 21 10 2020
Statut: ppublish

Résumé

Parkinson's disease is characterized by loss of dopamine neurons in the substantia nigra

Identifiants

DOI: 10.1038/s41586-020-2388-4 PMID: 32581380 PMC: PMC7521455
pubmed: 32581380
doi: 10.1038/s41586-020-2388-4
pii: 10.1038/s41586-020-2388-4
pmc: PMC7521455
mid: NIHMS1594393
doi:

Substances chimiques

Heterogeneous-Nuclear Ribonucleoproteins 0
PTBP1 protein, human 0
Ptbp1 protein, mouse 0
Polypyrimidine Tract-Binding Protein 139076-35-0
Dopamine VTD58H1Z2X

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

550-556

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM049369
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM052872
Pays : United States
Organisme : NIH HHS
ID : GM052872
Pays : United States
Organisme : NIH HHS
ID : GM049369
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn

Références

Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Primers 3, 17013 (2017).
pubmed: 28332488 doi: 10.1038/nrdp.2017.13
Barker, R. A., Götz, M. & Parmar, M. New approaches for brain repair—from rescue to reprogramming. Nature 557, 329–334 (2018).
pubmed: 29769670 doi: 10.1038/s41586-018-0087-1
Sonntag, K. C. et al. Pluripotent stem cell-based therapy for Parkinson’s disease: current status and future prospects. Prog. Neurobiol. 168, 1–20 (2018).
pubmed: 29653250 pmcid: 6077089 doi: 10.1016/j.pneurobio.2018.04.005
Cohen, D. E. & Melton, D. Turning straw into gold: directing cell fate for regenerative medicine. Nat. Rev. Genet. 12, 243–252 (2011).
pubmed: 21386864 doi: 10.1038/nrg2938
Yu, X., Nagai, J. & Khakh, B. S. Improved tools to study astrocytes. Nat. Rev. Neurosci. 21, 121–138 (2020).
pubmed: 32042146 doi: 10.1038/s41583-020-0264-8
Rivetti di Val Cervo, P. et al. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model. Nat. Biotechnol. 35, 444–452 (2017).
pubmed: 28398344 doi: 10.1038/nbt.3835
Wu, Z. et al. Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington’s disease. Nat. Commun. 11, 1105 (2020).
pubmed: 32107381 pmcid: 7046613 doi: 10.1038/s41467-020-14855-3
Gascón, S., Masserdotti, G., Russo, G. L. & Götz, M. Direct Neuronal Reprogramming: Achievements, Hurdles, and New Roads to Success. Cell Stem Cell 21, 18–34 (2017).
pubmed: 28686866 doi: 10.1016/j.stem.2017.06.011
Xue, Y. et al. Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell 152, 82–96 (2013).
pubmed: 23313552 pmcid: 3552026 doi: 10.1016/j.cell.2012.11.045
Xue, Y. et al. Sequential regulatory loops as key gatekeepers for neuronal reprogramming in human cells. Nat. Neurosci. 19, 807–815 (2016).
pubmed: 27110916 pmcid: 4882254 doi: 10.1038/nn.4297
Hu, J., Qian, H., Xue, Y. & Fu, X. D. PTB/nPTB: master regulators of neuronal fate in mammals. Biophys. Rep. 4, 204–214 (2018).
pubmed: 30310857 pmcid: 6153489 doi: 10.1007/s41048-018-0066-y
Bennett, C. F., Krainer, A. R. & Cleveland, D. W. Antisense Diseases. Annu. Rev. Neurosci. 42, 385–406 (2019).
pubmed: 31283897 pmcid: 7427431 doi: 10.1146/annurev-neuro-070918-050501
Guo, Z. et al. In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model. Cell Stem Cell 14, 188–202 (2014).
pubmed: 24360883 doi: 10.1016/j.stem.2013.12.001
Lu, T. et al. REST and stress resistance in ageing and Alzheimer’s disease. Nature 507, 448–454 (2014).
pubmed: 24670762 pmcid: 4110979 doi: 10.1038/nature13163
Li, Q. et al. The splicing regulator PTBP2 controls a program of embryonic splicing required for neuronal maturation. eLife 3, e01201 (2014).
pubmed: 24448406 pmcid: 3896118 doi: 10.7554/eLife.01201
Laywell, E. D., Rakic, P., Kukekov, V. G., Holland, E. C. & Steindler, D. A. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc. Natl Acad. Sci. USA 97, 13883–13888 (2000).
pubmed: 11095732 pmcid: 17670 doi: 10.1073/pnas.250471697
Sofroniew, M. V. Transgenic techniques for cell ablation or molecular deletion to investigate functions of astrocytes and other GFAP-expressing cell types. Methods Mol. Biol. 814, 531–544 (2012).
pubmed: 22144330 doi: 10.1007/978-1-61779-452-0_35
Tateno, T. & Robinson, H. P. The mechanism of ethanol action on midbrain dopaminergic neuron firing: a dynamic-clamp study of the role of I(h) and GABAergic synaptic integration. J. Neurophysiol. 106, 1901–1922 (2011).
pubmed: 21697445 doi: 10.1152/jn.00162.2011
Kimm, T., Khaliq, Z. M. & Bean, B. P. Differential regulation of action potential shape and burst-frequency firing by BK and Kv2 Channels in substantia nigra dopaminergic neurons. J. Neurosci. 35, 16404–16417 (2015).
pubmed: 26674866 pmcid: 4679822 doi: 10.1523/JNEUROSCI.5291-14.2015
Boisvert, M. M., Erikson, G. A., Shokhirev, M. N. & Allen, N. J. The aging astrocyte transcriptome from multiple regions of the mouse brain. Cell Rep. 22, 269–285 (2018).
pubmed: 29298427 pmcid: 5783200 doi: 10.1016/j.celrep.2017.12.039
Nott, A. et al. Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science 366, 1134–1139 (2019).
pubmed: 31727856 pmcid: 7028213 doi: 10.1126/science.aay0793
Grealish, S. et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson’s disease. Cell Stem Cell 15, 653–665 (2014).
pubmed: 25517469 pmcid: 4232736 doi: 10.1016/j.stem.2014.09.017
Thiele, S. L., Warre, R. & Nash, J. E. Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson’s disease. J. Vis. Exp. 60, 3234 (2012).
Beal, M. F. Parkinson’s disease: a model dilemma. Nature 466, S8–S10 (2010).
pubmed: 20739935 doi: 10.1038/466S8a
Stott, S. R. & Barker, R. A. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson’s disease. Eur. J. Neurosci. 39, 1042–1056 (2014).
pubmed: 24372914 doi: 10.1111/ejn.12459
Boix, J., Padel, T. & Paul, G. A partial lesion model of Parkinson’s disease in mice—characterization of a 6-OHDA-induced medial forebrain bundle lesion. Behav. Brain Res. 284, 196–206 (2015).
pubmed: 25698603 doi: 10.1016/j.bbr.2015.01.053
Zhu, H. & Roth, B. L. DREADD: a chemogenetic GPCR signaling platform. Int. J. Neuropsychopharmacol. 18, pyu007 (2015).
doi: 10.1093/ijnp/pyu007
Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S. & Roth, B. L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc. Natl Acad. Sci. USA 104, 5163–5168 (2007).
pubmed: 17360345 pmcid: 1829280 doi: 10.1073/pnas.0700293104
Chen, Y. et al. Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson’s disease. Cell Stem Cell 18, 817–826 (2016).
pubmed: 27133795 pmcid: 4892985 doi: 10.1016/j.stem.2016.03.014
Zhou, H. et al. Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice. Cell 181, 590-603 (2020).
Ouyang, H. et al. WNT7A and PAX6 define corneal epithelium homeostasis and pathogenesis. Nature 511, 358–361 (2014).
pubmed: 25030175 pmcid: 4610745 doi: 10.1038/nature13465
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10–12 (2011).
doi: 10.14806/ej.17.1.200
Srivastava, A., Malik, L., Smith, T., Sudbery, I. & Patro, R. Alevin efficiently estimates accurate gene abundances from dscRNA-seq data. Genome Biol. 20, 65 (2019).
pubmed: 30917859 pmcid: 6437997 doi: 10.1186/s13059-019-1670-y
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Abercrombie, M. Estimation of nuclear population from microtome sections. Anat. Rec. 94, 239–247 (1946).
pubmed: 21015608 doi: 10.1002/ar.1090940210
Falk, T. et al. Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson’s disease. Neurosci. Lett. 496, 43–47 (2011).
pubmed: 21507340 doi: 10.1016/j.neulet.2011.03.088
Baker, H., Joh, T. H. & Reis, D. J. Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: relationship to size and neuronal density of the striatum. Proc. Natl Acad. Sci. USA 77, 4369–4373 (1980).
pubmed: 6107905 pmcid: 349836 doi: 10.1073/pnas.77.7.4369
Kordower, J. H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 290, 767–773 (2000).
pubmed: 11052933 doi: 10.1126/science.290.5492.767
Bahat-Stroomza, M. et al. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson’s disease. J. Mol. Neurosci. 39, 199–210 (2009).
pubmed: 19127447 doi: 10.1007/s12031-008-9166-3
Liu, G., Chen, J. & Ma, Y. Simultaneous determination of catecholamines and polyamines in PC-12 cell extracts by micellar electrokinetic capillary chromatography with ultraviolet absorbance detection. J. Chromatogr. B 805, 281–288 (2004).
doi: 10.1016/j.jchromb.2004.03.011
De Benedetto, G. E. et al. A rapid and simple method for the determination of 3,4-dihydroxyphenylacetic acid, norepinephrine, dopamine, and serotonin in mouse brain homogenate by HPLC with fluorimetric detection. J. Pharm. Biomed. Anal. 98, 266–270 (2014).
pubmed: 24971521 doi: 10.1016/j.jpba.2014.05.039
Tareke, E., Bowyer, J. F. & Doerge, D. R. Quantification of rat brain neurotransmitters and metabolites using liquid chromatography/electrospray tandem mass spectrometry and comparison with liquid chromatography/electrochemical detection. Rapid Commun. Mass Sp. 21, 3898–3904 (2007).
doi: 10.1002/rcm.3295
Wang, S. R. et al. Role of vesicle pools in action potential pattern-dependent dopamine overflow in rat striatum in vivo. J. Neurochem. 119, 342–353 (2011).
pubmed: 21854394 doi: 10.1111/j.1471-4159.2011.07440.x
Xu, H. et al. Striatal dopamine release in a schizophrenia mouse model measured by electrochemical amperometry in vivo. Analyst 140, 3840–3845 (2015).
pubmed: 25651802 doi: 10.1039/C4AN02074J
Wang, C. et al. Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson’s disease-like pathology. Nat. Commun. 9, 81 (2018).
pubmed: 29311685 pmcid: 5758517 doi: 10.1038/s41467-017-02593-y
Wang, L. et al. Modulation of dopamine release in the striatum by physiologically relevant levels of nicotine. Nat. Commun. 5, 3925 (2014).
pubmed: 24968237 doi: 10.1038/ncomms4925
Caiazzo, M. et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476, 224–227 (2011).
pubmed: 21725324 doi: 10.1038/nature10284
Grealish, S., Mattsson, B., Draxler, P. & Björklund, A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson’s disease. Eur. J. Neurosci. 31, 2266–2278 (2010).
pubmed: 20529122 doi: 10.1111/j.1460-9568.2010.07265.x
Piallat, B., Benazzouz, A. & Benabid, A. L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur. J. Neurosci. 8, 1408–1414 (1996).
pubmed: 8758948 doi: 10.1111/j.1460-9568.1996.tb01603.x
Dunnett, S. B., Björklund, A., Stenevi, U. & Iversen, S. D. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions. Brain Res. 215, 147–161 (1981).
pubmed: 7260584
Iancu, R., Mohapel, P., Brundin, P. & Paul, G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav. Brain Res. 162, 1–10 (2005).
pubmed: 15922062 doi: 10.1016/j.bbr.2005.02.023
Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Academic Press, 1988).
Cohen, J. Eta-squared and partial eta-squared in fixed factor ANOVA designs. Educ. Psychol. Meas. 33, 107–112 (1973).
doi: 10.1177/001316447303300111

Auteurs

Hao Qian (H)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.

Xinjiang Kang (X)

State Key Laboratory of Membrane Biology and Peking-Tsinghua Center for Life Sciences, Institute of Molecular Medicine, Peking University, Beijing, China.
MOE Key Lab of Medical Electrophysiology, ICR, Southwest Medical University, Luzhou, China.

Jing Hu (J)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Dongyang Zhang (D)

Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
ORCID: 0000-0003-2365-4763

Zhengyu Liang (Z)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.

Fan Meng (F)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.

Xuan Zhang (X)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.

Yuanchao Xue (Y)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
ORCID: 0000-0002-8113-2333

Roy Maimon (R)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA, USA.

Steven F Dowdy (SF)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.

Neal K Devaraj (NK)

Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
ORCID: 0000-0002-8033-9973

Zhuan Zhou (Z)

State Key Laboratory of Membrane Biology and Peking-Tsinghua Center for Life Sciences, Institute of Molecular Medicine, Peking University, Beijing, China.
ORCID: 0000-0001-9048-6638

William C Mobley (WC)

Department of Neurosciences and Center for Neural Circuits and Behavior, University of California, San Diego, La Jolla, CA, USA.

Don W Cleveland (DW)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA, USA.
ORCID: 0000-0002-1934-3682

Xiang-Dong Fu (XD)

Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA. xdfu@ucsd.edu.
Institute of Genomic Medicine, University of California, San Diego, La Jolla, CA, USA. xdfu@ucsd.edu.
ORCID: 0000-0001-5499-8732

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Cellules › Névroglie › Astrocytes › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Cellules › Neurones › Neurofibres › Axones › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Dopamine › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Cellules › Neurones › Neurones dopaminergiques › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › Protéines à motif de reconnaissance de l'ARN › Ribonucléoprotéines nucléaires hétérogènes › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Noyaux gris centraux › Corps strié › Néostriatum › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Système nerveux › Voies nerveuses › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Neurogenèse › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Maladies du système nerveux › Maladies neurodégénératives › Maladie de Parkinson › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Phénomènes génétiques › Phénotype › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Nucléoprotéines › Protéines de liaison à l'ARN › Facteurs d'épissage des ARN › Protéine PTB › Reversing a model of Parkinson's disease with...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Tronc cérébral › Mésencéphale › Pédoncule cérébral › Substantia nigra › Reversing a model of Parkinson's disease with...